Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Call number: QZ365WI435:100
    Keywords: Colorectal Neoplasms ; Colorectal Neoplasms / diagnosis ; Colorectal Neoplasms / therapy ; Radiotherapy
    Pages: viii, 95 p. : ill.
    ISBN: 9781891483608
    Signatur Availability
    QZ365WI435:100 available
    BibTip Others were also interested in ...
  • 2
    facet.materialart.
    New York, NY : Springer
    Keywords: Oncology ; Oncology   ; Medical laboratories ; Internal Medicine ; Medicine ; Toxicology ; Cancer Research ; Oncology ; Laboratory Medicine ; Internal Medicine ; Molecular Medicine ; Pharmacology/Toxicology ; Springer Nature Living Reference
    Abstract: In the past decade, we have experienced an explosion of new information about cancer therapeutic targets. Many of the targets have been validated by the discovery and approval of new medicines which have been approved for the treatment of cancer. On the heels of these successes, innumerable new targets and new potential therapeutics are being developed by many different groups including government agencies, pharmaceutical companies, biotechnology companies, academic institutions, and individual investigators. Understanding the expanding "universe" of cancer therapies is therefore becoming impossible and no single source exists which serves as a reference for the involved parties. Further, the interested parties have vastly different areas of expertise, from focused laboratory based science, to clinical research, to corporate and regulatory oversight. The text would be updated every two years, more often depending on pace of change, interest and sales. While useful online, this reference book would likely be kept in hard copy as well
    Pages: 800 p. 164 illus., 64 illus. in color. : online resource.
    ISBN: 9781461466130
    Signatur Availability
    BibTip Others were also interested in ...
  • 3
    facet.materialart.
    New York, NY : Springer New York
    Keywords: Medicine ; Cancer Research ; Laboratory Medicine ; Molecular Biology ; Pharmacology ; Internal Medicine ; Oncology ; Biomedicine ; Cancer Research ; Oncology ; Laboratory Medicine ; Internal Medicine ; Molecular Medicine ; Pharmacology/Toxicology ; Springer eBooks
    Description / Table of Contents: AKT -- Anti-4-1BB/4-1BBL -- Anti-B7-H4 -- Anti-CD40/Anti CD40L -- Anti-Idiotype antibodies -- Anti-Programmed Death 1 (PD1) -- B7.1 -- Bacterial Vaccines -- Brachyury -- CCL21 -- CD4+ T Cells -- CD8 T Cells -- CEA -- CTLA-4 -- Dendritic cells -- DNA Vaccines -- EGFR, Immunology -- Fc Gamma R -- Gangliosides -- Glucocorticoid-Induced TNF Receptor (GITR) -- GM-CSF and Whole Cells -- gp100 -- HER2/neu -- indoleamine 2,3-dioxygenase -- Integrins, Immunology -- Interferon alpha -- Interleukin 2 -- Interleukin 7 -- Interleukin 12 -- Interleukin 15 -- Interleukin 21 -- Lymphocyte Activation Gene 3 (LAG-3) -- MART-1 -- MUC1 -- NK Cells -- P53, Immunology -- PAP -- Peptide Vaccine: Overview -- Proteins (Mesothelin) -- PSA -- Survivin -- Telomerase-related proteins -- TGF Beta Receptors -- TLR7 and TLR8, Resiquimod, and 852A -- TLR9 -- Transforming Growth Factor β -- Tregs -- Tyrosinase: Overview -- VEGF -- Viral-Like Proteins -- Whole-Cell Vaccines -- FGF-FGFR Signaling in Cancer -- MMPs -- PDGF -- TIE -- VEGF A -- VEGF Ligands -- AXL -- B-Raf -- CKIT -- DNA Repair, Overview -- EGFR, Growth factors -- HER3 -- IGF 1 and IGF 2 -- Jak2/Stat5a/b Pathway in Prostate Cancer -- JNK Signaling in Diseases -- K-Ras -- MET -- NEDD9 -- N-Ras -- P38 -- Rac 1 -- Type I Insulin-Like Growth Factor Receptor -- Anti-apoptotic Bcl-2 -- BH3-Only Mimetics -- Caspase -- DR4 and DR5 -- FLIP -- MLH1 -- NF-κB -- PARP -- ROS -- X-Linked IAP -- APC -- AR, Overview -- BRCA 1 and 2 -- Cell Cycle Related Kinases -- ER -- Histone Deacetylases (HDAC) -- Methylation -- PR -- Retinoids -- Topoisomerase 1 -- Topoisomerase 2 -- VDR
    Abstract: In the past decade, we have experienced an explosion of new information about cancer therapeutic targets. Many of the targets have been validated by the discovery and approval of new medicines which have been approved for the treatment of cancer. On the heels of these successes, innumerable new targets and new potential therapeutics are being developed by many different groups including government agencies, pharmaceutical companies, biotechnology companies, academic institutions, and individual investigators. Understanding the expanding "universe" of cancer therapies is therefore becoming impossible and no single source exists which serves as a reference for the involved parties. Further, the interested parties have vastly different areas of expertise, from focused laboratory based science, to clinical research, to corporate and regulatory oversight. The text would be updated every two years, more often depending on pace of change, interest and sales. While useful online, this reference book would likely be kept in hard copy as well
    Pages: 51 illus., 42 illus. in color. eReference. : online resource.
    ISBN: 9781441907172
    Signatur Availability
    BibTip Others were also interested in ...
  • 4
    ISSN: 1432-0851
    Keywords: Key words Avipox-CEA ; ELISPOT assay ; CEA peptide ; Immune responses ; Cancer vaccine ; Carcinoma
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract An enzyme-linked immunosorbent spot (ELISPOT) assay for interferon γ production has been used to analyze specific T cell responses to a Flu 9-mer peptide, and a 9-mer peptide of carcinoembryonic antigen (CEA). Assays were performed on peripheral blood mononuclear cells (PBMC) of HLA-A2-positive patients with CEA-expressing carcinomas, both before and after vaccination with CEA-based vaccines, and from HLA-A2-positive healthy blood donors. The ELISPOT assay utilized aliquots of frozen PBMC, and assays were performed after 24 h in culture with peptide to rule out any artifacts due to long-term in vitro stimulation cycles. An internal standard was used for each assay to define reproducibility of the assay, and all samples from a given patient (pre- and post-vaccination, with both the Flu and CEA peptides) were analyzed simultaneously. The results indicated a trend towards healthy blood donors having higher levels of Flu-specific T cell precursors than do colon carcinoma patients, but these results were not statistically significant (P = 0.06). On the other hand, slightly higher CEA-specific T cell responses were observed in cancer patients with CEA-expressing carcinomas than in healthy blood donors. PBMC from two CEA-based vaccine clinical trials were analyzed for T cell responses to the same CEA peptide and to the Flu control peptide. The first trial consisted of three monthly vaccinations of CEA peptide (designated PPP) in adjuvant. The second trial consisted of cohorts receiving three monthly vaccinations of avipox-CEA recombinant (designated AAA) or cohorts receiving a primary vaccination with recombinant vaccinia-CEA followed by two monthly vaccinations with avipox-CEA (designated VAA). Few, if any, CEA-specific T cell responses were seen in the PPP vaccinations, while the majority of patients receiving the poxvirus CEA recombinants demonstrated increases in CEA-specific T cell responses and no increases in Flu-specific responses. CEA-specific IgG responses were also demonstrated in patients following recombinant CEA poxvirus vaccinations. Statistical analyses of the T cell responses to the same CEA peptide demonstrated a P value of 0.028 for the recombinant poxvirus vaccines, as compared with the peptide vaccine. There were no differences seen (P = 0.37) in Flu-specific responses after these two types of CEA vaccination. These results thus provide the first evidence that poxvirus recombinant-based vaccines are more potent in the initiation of tumor-antigen-specific T cell responses than vaccines employing peptide in adjuvant, when assays are conducted in an identical manner, and in defining responses to the same peptide. These results also demonstrate for the first time that an ELISPOT assay, performed over a 24-h period and without in vitro sensitization, can be successfully used to monitor immune responses to a tumor-associated antigen in cancer patients.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 5
    ISSN: 1520-6904
    Source: ACS Legacy Archives
    Topics: Chemistry and Pharmacology
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 6
    ISSN: 1573-7217
    Keywords: angiogenesis inhibitors ; basic FGF ; advanced cancer ; Phase 1 ; human trials ; pentosan polysulfate
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Antiangiogenic agents have been recently recognized to be potentially useful in the treatment of malignant processes. There has been a resulting flood of these agents into the clinical research field, forcing researchers to consider the unique problems which these agents pose. As these are agents with a novel, angiostatic mechanism of action, new clinical trial designs may become necessary to move these agents from the phase 1 level on to clinical use. Currently, several of these agents are being or have been tested in clinical trials. In this article, we review the available clinical data with antiangiogenic agents from other investigators, and our own experience with pentosan polysulfate.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 7
    ISSN: 1520-6904
    Source: ACS Legacy Archives
    Topics: Chemistry and Pharmacology
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 8
    Electronic Resource
    Electronic Resource
    s.l. : American Chemical Society
    The @journal of organic chemistry 44 (1979), S. 626-628 
    ISSN: 1520-6904
    Source: ACS Legacy Archives
    Topics: Chemistry and Pharmacology
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 9
    ISSN: 1520-6904
    Source: ACS Legacy Archives
    Topics: Chemistry and Pharmacology
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 10
    ISSN: 0021-9304
    Keywords: Chemistry ; Polymer and Materials Science
    Source: Wiley InterScience Backfile Collection 1832-2000
    Topics: Medicine , Technology
    Additional Material: 3 Ill.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...